Cullinan Therapeutics, Inc. (CGEM)
Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
17. 69
+1.28
+7.8001%
$
1.09B Market Cap
- P/E Ratio
- Div Yield
594,700 Volume
- Eps
$ 16.41
Previous Close 
Want to track CGEM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating exon 20 insertion mutation-positive NSCLC, with a 40% objective response rate in early phase trials. CGEM has a strong financial position with cash reserves projected to fund operations into 2028, reducing the need for immediate equity raises.
Seekingalpha | 1 year ago
